STOCK TITAN

MAK Capital reports 5.3% Evotec (EVO) stake in Schedule 13G filing

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

Evotec SE received a Schedule 13G filing from investment entities associated with MAK Capital, disclosing a significant passive ownership position. MAK Capital Fund LP, MAK Capital One L.L.C., and Michael A. Kaufman together report beneficial ownership of 9,386,434 Ordinary Shares, representing 5.3% of Evotec’s Ordinary Shares outstanding as of January 9, 2026, based on the issuer’s website disclosure of 177,778,907 shares. The reporting persons indicate they hold shared power to vote and dispose of these shares and certify that the securities were not acquired and are not held for the purpose of changing or influencing control of Evotec SE.

Positive

  • None.

Negative

  • None.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person: For item 11: The calculation is based upon 177,778,907 Ordinary Shares (including Ordinary Shares in the form of American Depositary Shares, each representing one-half of one Ordinary Share), outstanding as of January 9, 2026, as reported by the Issuer on its website.


SCHEDULE 13G




Comment for Type of Reporting Person: For item 11: The calculation is based upon 177,778,907 Ordinary Shares (including Ordinary Shares in the form of American Depositary Shares, each representing one-half of one Ordinary Share), outstanding as of January 9, 2026, as reported by the Issuer on its website.


SCHEDULE 13G




Comment for Type of Reporting Person: For item 11: The calculation is based upon 177,778,907 Ordinary Shares (including Ordinary Shares in the form of American Depositary Shares, each representing one-half of one Ordinary Share), outstanding as of January 9, 2026, as reported by the Issuer on its website.


SCHEDULE 13G



MAK Capital Fund LP
Signature:/s/ Michael A. Kaufman
Name/Title:Managing Member
Date:01/16/2026
MAK Capital One L.L.C.
Signature:/s/ Michael A. Kaufman
Name/Title:Managing Member
Date:01/16/2026
Michael A. Kaufman
Signature:/s/ Michael A. Kaufman
Name/Title:MICHAEL A. KAUFMAN
Date:01/16/2026

FAQ

Who is the new 5.3% shareholder of Evotec (EVO) disclosed in this Schedule 13G?

The Schedule 13G shows that MAK Capital Fund LP, MAK Capital One L.L.C., and Michael A. Kaufman (together, the reporting persons) beneficially own Evotec SE Ordinary Shares.

How many Evotec SE shares does MAK Capital report owning in this filing?

The reporting persons disclose beneficial ownership of 9,386,434 Evotec SE Ordinary Shares, including shares represented by American Depositary Shares, as stated in the ownership section.

What percentage of Evotec SE’s share capital is owned by MAK Capital according to the Schedule 13G?

The filing states that the reporting persons beneficially own 5.3% of Evotec SE’s Ordinary Shares, based on 177,778,907 Ordinary Shares outstanding as of January 9, 2026.

Is MAK Capital’s Evotec (EVO) position reported as active or passive ownership?

The certification in Item 10 states that the securities were not acquired and are not held for the purpose of changing or influencing the control of Evotec SE, indicating a passive ownership status under Schedule 13G.

Who signed the Evotec Schedule 13G on behalf of the reporting persons?

Michael A. Kaufman signed the statement multiple times, including as Managing Member, certifying that the information in the Schedule 13G is true, complete, and correct.

What type of reporting persons are identified for this Evotec Schedule 13G filing?

The filing classifies MAK Capital Fund LP as PN (a limited partnership), MAK Capital One L.L.C. as IA (investment adviser), and Michael A. Kaufman as IN (individual) for Item 12.

Evotec Ag

NASDAQ:EVO

EVO Rankings

EVO Latest News

EVO Latest SEC Filings

EVO Stock Data

1.28B
355.28M
2.72%
0.21%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
Germany
Hamburg